Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04099602
Other study ID # EgeU
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 6, 2018
Est. completion date July 18, 2019

Study information

Verified date September 2019
Source Ege University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Jaundice (hyperbilirubinemia) which is one of the common causes of repeated hospitalizations in the neonatal period, is a physiological condition seen in 60% of term babies and 80% of premature babies in the first week of life . Premature babies are more susceptible tobilirubin neurotoxicity. Death and severe sequelae due to hyperbilirubinemia can be prevented by early diagnosis and treatment. Massage is one of the applications that can be used to reduce bilirubin levels in newborn infants. Baby massage facilitates bowel movements and bilirubin excretion by reducing enterohepatic circulation. This study was designed as a randomized controlled trial to investigate the effect of massage on bilirubin levels in premature infants.


Description:

Neonatal jaundice is a physiological condition seen in 60% of infants and 80% of preterm infants in the first week of life. There is no clear data on the frequency of jaundice in newborns in our country. Jaundice is one of the common causes of 75% of hospitalizations in the first week after birth and the recurrence of hospitalizations in the neonatal period. Neonatal jaundice is a non-hazardous and transient condition that can usually resolve spontaneously without treatment. Although it is a transient condition, high bilirubin levels can cause kernicterus which causes severe neurological damage if not diagnosed and treated early .

The severity and complications of hyperbilirubinemia in premature infants are different from term infants. Premature infants are more susceptible to damage caused by serum bilirubin, even at low levels of brain cells. Hyperbilirubinemia in preterm infants is more prevalent, severe, and protracted than that in term infants because of the immaturity of their red blood cells, livers, and gastrointestinal tracts. There also is often a delay in enteral feeds, which may limit intestinal flow and bacterial colonization, resulting in further enhancement of the enterohepatic circulation of bilirubin. Preterm neonates are more susceptible to bilirubin neurotoxicity. Almost all preterm infants less than 35 weeks gestational age have elevated total serum/plasma bilirubin levels, which results in neonatal jaundice, the yellowish discoloration of the skin and conjunctiva caused by bilirubin deposition. The major complication of an elevated total serum (hyperbilirubinemia) is bilirubin-induced neurologic dysfunction (BIND), which occurs when circulating bilirubin crosses the blood-brain barrier and binds to brain tissue . Jaundice is an important problem in newborn infants and death and severe sequelae due to hyperbilirubinemia can be prevented by early diagnosis and treatment. Various treatment methods have been developed to reduce bilirubin levels. The most commonly used methods are; blood exchange, phototherapy and pharmacological agents. Therapeutic interventions prevent BIND and thus kernicterus by lowering the level of bilirubin in the blood. Phototherapy is a common treatment for both treatment and prevention of increased bilirubin levels. Phototherapy has been widely used in the treatment of hyperbilirubinemia of the newborn for more than fifty years. Phototherapy has various side effects, such as damage to the retina and genitalia, loss of body water, skin rashes, watery stools and Bronze Baby Syndrome.

Nowadays, studies on new treatment methods and different applications are being made which support the treatment of jaundice and shorten the length of hospital stay. Kangaroo care reduces the exposure of newborns to phototherapy, swimming, wiping and bathtub bathing have been reported to reduce bilirubin levels. Baby massage is one of the alternative and complementary therapies that can be used to reduce bilirubin levels.

While there are many studies investigating the effect of infant massage on bilirubin levels in term neonates with healthy and hyperbilirubinemia, a limited number of studies investigating the effect of massage on bilirubin levels in premature infants were found.

It is suggested that baby massage can be performed by trained nurses and mothers trained by nurses. Infant massage stimulates defecation by increasing bowel movements, thus decreasing enterohepatic circulation and increasing bilirubin excretion. Bilirubin excretion decreases the speed and severity of hyperbilirubinemia. In some studies investigating the effect of massage on bilirubin levels, transcutaneous bilirubin (TcB) levels or TSB levels were found to be significantly lower, also no significant difference was found in some studies.

In our country, the studies on the benefits of baby massage for infants are quite new. There are two studies investigating the effect of massage on bilirubin levels in newborn infants. However, in one of these studies, the effect of infant massage on bilirubin levels in newborns who received phototherapy was investigated, while the effect of abdominal massage on TcB bilirubin levels in newborns was investigated in the other study. TSB levels are the gold standard in the evaluation of bilirubin levels in newborn infants. However, the blood needs to be taken from the baby, and taking blood is a painful procedure, and it may not always possible to get enough blood. Measurement of bilirubin level from the skin surface is both noninvasive, painless and simple. In this study, the effect of infant massage on bilirubin level in premature infants not receiving phototherapy was evaluated by transcutaneous bilirubin measurement method. This study was designed as a randomized controlled trial to investigate the effect of massage on bilirubin levels in premature infants.


Recruitment information / eligibility

Status Completed
Enrollment 64
Est. completion date July 18, 2019
Est. primary completion date April 6, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 32 Weeks to 38 Months
Eligibility Inclusion Criteria:

- families being voluntary to participate in the study

- infants being born between 32 and 37 weeks plus 6 days of gestation

- infants having a birth weight of =1500 g

- infants having a fifth-minute Apgar score of more than seven

- infant's bilirubin level is not sufficient to require phototherapy

- the vital signs of the baby are within normal limits

- the absence of congenital major malformation of the infants

- the lack of patent ductus arteriosus requiring treatment

- no proven sepsis diagnosis

Exclusion Criteria:

- neonates with disease disrupting skin integrity (epidermolysis bullosa, ichthyosis, collodion baby)

- need for phototherapy

- infants with gastrointestinal obstruction and biliary atresia

- infants with congenital major deformations

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Baby Massage
Received baby massage and bilirubin levels were measured twice daily by the transcutaneous bilirubin meter for 5 days

Locations

Country Name City State
Turkey Ege University Faculty of Nursing Izmir Bornova

Sponsors (1)

Lead Sponsor Collaborator
Ege University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Other length of hospital stay number of days in hospital "through study completion, an average of 1 year"
Primary Transcutaneous Bilirubin Levels bilirubin level mg/dl "through study completion, an average of 1 year"
Secondary frequency of defecation daily number "through study completion, an average of 1 year"
See also
  Status Clinical Trial Phase
Recruiting NCT04365998 - BUBOLight®, a New Phototherapy Device for the Treatment of the Newborn's Jaundice N/A
Completed NCT02222805 - Effect of Timing of Umbilical Cord Clamping on Anaemia at 8 and 12 Months and Later Neurodevelopment N/A
Completed NCT01622699 - Implementation of a Transcutaneous Bilirubinometer N/A
Completed NCT00692224 - Efficacy of Zinc in Reducing Hyperbilirubinemia Among High Risk Neonates - A Double Blind Randomized Trial Phase 1/Phase 2
Not yet recruiting NCT06080971 - Persistent Neonatal Jaundice on Neonates and Childern
Recruiting NCT06075290 - the Difference of Follow-up Methods of Neonatal Jaundice
Recruiting NCT05955144 - Clinical Validation of the Screening Tool Picterus JP Using Different Smartphones N/A
Recruiting NCT05127070 - Evaluating the NeoTree in Malawi and Zimbabwe
Completed NCT03306004 - Neonatal Jaundice: Knowledge, Attitudes and Practices of Mothers and Medical Trainees and Providers in and Around Ogbomosho N/A
Completed NCT02774434 - Efficacy Study of the Draeger Jaundice Meter (JM-105) in Neonates of ≥ 24 Weeks of Gestational Age N/A
Terminated NCT05365399 - Evaluation of a Smartphone-based Screening Tool for Neonatal Jaundice in a Ugandan Population N/A
Recruiting NCT03933423 - Home Based Phototherapy for Neonatal Jaundice N/A
Recruiting NCT03183986 - Comparison of the Efficacy of Phototherapy Using Blue LED's With Wavelength 478 vs. 459 nm. N/A
Withdrawn NCT00917007 - Measurement of Carboxyhemoglobin by Gas Chromatography as an Index of Hemolysis
Completed NCT06227624 - Role of Oral Zinc in Reducing Neonatal Indirect Hyperbilirubinemia Phase 3
Completed NCT04433923 - Aluminium Foil as an Adjuvant to Phototherapy for Pathological Unconjugated Hyperbilirubinaemia in Full Term Infants N/A
Completed NCT04418180 - Fenofibrate Therapy in Pathological Unconjugated Hyperbilirubinemia in Full Term Infants N/A
Completed NCT06386731 - Continuous Versus Intermittent Phototherapy in Treatment of Neonatal Jaundice N/A
Not yet recruiting NCT05475223 - End Tidal Carbon Monoxide (ETCO): - A Tool to Aid Identification of Neonatal Hemolysis N/A
Recruiting NCT03237715 - Unbound Bilirubin Levels in Healthy Term and Late Preterm Infants N/A